Biogen’s stock hit by soft sales of Alzheimer’s treatment
Read more at MarketWatch
Topics
-
Biogen’s stock rises after E.U. regulator reverses negative view of Alzheimer’s drug
Business - MarketWatch - November 14 -
Biogen tops estimates, raises profit guidance as Alzheimer's drug Leqembi gains traction
Business - CNBC - October 30 -
Costco shoppers stocked up on supplies as hurricanes, port strike hit. The trend hurt sales in October.
Business - MarketWatch - November 7 -
4 retail stocks that look good even if the holiday shopping season is soft
Business - CNBC - November 2 -
Western consumer groups unconvinced by China’s economic stimulus efforts
Business - Financial Times - October 31 -
Mercedes-Benz and Porsche look for cost cuts after China slump hits profits
Business - Financial Times - October 25 -
Stellantis hit by sales slide in US and Europe
World - Financial Times - October 31 -
This biotech’s stock could double if its treatment for major depressive disorder succeeds, says Mizuho
Business - MarketWatch - November 14
More from MarketWatch
-
Trump’s Treasury pick is Scott Bessent. He’s said it’s absurd to fear ‘Trump-flation.’
Business - MarketWatch - 7 hours ago -
Investors can look ahead to Nvidia, Treasury bonds and a bullish finish to 2024
Business - MarketWatch - 10 hours ago -
Hoping for an OpenAI or Anthropic IPO? Here’s why that’s unlikely anytime soon.
Business - MarketWatch - 10 hours ago -
Qualcomm is moving fast to boost growth and trim its dependence on Apple
Business - MarketWatch - 10 hours ago -
Nvidia continues its march to a $4 trillion stock-market valuation. Why it’s inevitable.
Business - MarketWatch - 11 hours ago